{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T13:52:27Z","timestamp":1791985947173,"version":"4.4.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004917","name":"Cancer Prevention Research Institute of Texas","doi-asserted-by":"crossref","award":["RP130051"],"award-info":[{"award-number":["RP130051"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Institute On Aging of the National Institutes of Health","award":["R01AG058971"],"award-info":[{"award-number":["R01AG058971"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Epidemiology"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.canep.2018.12.002","type":"journal-article","created":{"date-parts":[[2018,12,5]],"date-time":"2018-12-05T20:24:13Z","timestamp":1544041453000},"page":"89-97","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Increase in survival for patients with mantle cell lymphoma in the era of novel agents in 1995\u20132013: Findings from Texas and national SEER areas"],"prefix":"10.1016","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6461-0746","authenticated-orcid":false,"given":"Shuangshuang","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruosha","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Lairson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianglin L.","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.canep.2018.12.002_bib0005","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/00000478-199207000-00001","article-title":"Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data","volume":"16","author":"Banks","year":"1992","journal-title":"Am. J. Surg. Pathol."},{"issue":"11","key":"10.1016\/j.canep.2018.12.002_bib0010","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"A clinical evaluation of the International Lymphoma Study Group classification of Non-hodgkin\u2019s lymphoma. The Non-hodgkin\u2019s lymphoma classification project","volume":"89","year":"1997","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.canep.2018.12.002_bib0015","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.3109\/10428194.2012.760041","article-title":"An upward trend in the age-specific incidence patterns for mantle cell lymphoma in the USA","volume":"54","author":"Aschebrook-Kilfoy","year":"2013","journal-title":"Leuk. Lymphoma"},{"issue":"4","key":"10.1016\/j.canep.2018.12.002_bib0020","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/cncr.23608","article-title":"Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004","volume":"113","author":"Zhou","year":"2008","journal-title":"Cancer"},{"issue":"68","key":"10.1016\/j.canep.2018.12.002_bib0025","doi-asserted-by":"crossref","first-page":"112516","DOI":"10.18632\/oncotarget.22367","article-title":"Trends and variations in mantle cell lymphoma incidence from 1995 to 2013: a comparative study between Texas and National SEER areas","volume":"8","author":"Fu","year":"2017","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.canep.2018.12.002_bib0030","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1093\/annonc\/mdt070","article-title":"A phase II multicenter trial of hyperCVAD MTX\/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213","volume":"24","author":"Bernstein","year":"2013","journal-title":"Ann. Oncol."},{"issue":"30","key":"10.1016\/j.canep.2018.12.002_bib0035","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.canep.2018.12.002_bib0040","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.canep.2018.12.002_bib0045","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/bjh.13101","article-title":"Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma","volume":"168","author":"Furtado","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"7","key":"10.1016\/j.canep.2018.12.002_bib0050","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.canep.2018.12.002_bib0055","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2141.2012.09174.x","article-title":"Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur","volume":"158","author":"Geisler","year":"2012","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.canep.2018.12.002_bib0060","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdn656","article-title":"Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study","volume":"20","author":"Goy","year":"2009","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.canep.2018.12.002_bib0065","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","volume":"23","author":"Lenz","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.canep.2018.12.002_bib0070","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to evaluate temsirolimus compared with investigator\u2019s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma","volume":"27","author":"Hess","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.canep.2018.12.002_bib0075","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(12)70200-0","article-title":"Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1\/2 clinical trial","volume":"13","author":"Wang","year":"2012","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.canep.2018.12.002_bib0080","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"10121","key":"10.1016\/j.canep.2018.12.002_bib0085","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","article-title":"Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial","volume":"391","author":"Wang","year":"2018","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.canep.2018.12.002_bib0090","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma","volume":"367","author":"Kluin-Nelemans","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.canep.2018.12.002_bib0095","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1412096","article-title":"Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma","volume":"372","author":"Robak","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"9873","key":"10.1016\/j.canep.2018.12.002_bib0100","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet (London, England)"},{"issue":"11","key":"10.1016\/j.canep.2018.12.002_bib0105","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1200\/JCO.2012.45.9842","article-title":"Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation","volume":"31","author":"Visco","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.canep.2018.12.002_bib0110","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.3109\/10428194.2012.656628","article-title":"Survival trends in mantle cell lymphoma in the United States over 16 years 1992-2007","volume":"53","author":"Chandran","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.canep.2018.12.002_bib0115","unstructured":"Chapter II: Historical background and status of North American standards-Surveillance Epidemiology and End Results Program North American Association of Central Cancer Registries."},{"key":"10.1016\/j.canep.2018.12.002_bib0120","series-title":"United States Census Bureau","author":"QuickFacts Texas","year":"2015"},{"issue":"3","key":"10.1016\/j.canep.2018.12.002_bib0125","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1586\/17512433.1.3.391","article-title":"Modeling cumulative incidence function for competing risks data","volume":"1","author":"Zhang","year":"2008","journal-title":"Expert Rev. Clin. Pharmacol."},{"issue":"7447","key":"10.1016\/j.canep.2018.12.002_bib0130","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.328.7447.1073","article-title":"The logrank test","volume":"328","author":"Bland","year":"2004","journal-title":"BMJ"},{"issue":"24","key":"10.1016\/j.canep.2018.12.002_bib0135","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1200\/JCO.2007.12.9866","article-title":"Choice and interpretation of statistical tests used when competing risks are present","volume":"26","author":"Dignam","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"446","key":"10.1016\/j.canep.2018.12.002_bib0140","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J. Am. Stat. Assoc."},{"issue":"8","key":"10.1016\/j.canep.2018.12.002_bib0145","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1182\/blood-2014-03-559930","article-title":"Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study","volume":"124","author":"Abrahamsson","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.canep.2018.12.002_bib0150","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/bjh.15170","article-title":"Impact of novel therapies for mantle cell lymphoma in the real world setting: a report from the UK\u2019s Haematological Malignancy Research Network (HMRN)","volume":"181","author":"Smith","year":"2018","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.canep.2018.12.002_bib0155","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JCO.2008.16.8435","article-title":"Improvement of overall survival in advanced stage mantle cell lymphoma","volume":"27","author":"Herrmann","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"8 Suppl","key":"10.1016\/j.canep.2018.12.002_bib0160","article-title":"Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population","volume":"40","author":"Warren","year":"2002","journal-title":"Med. Care"}],"container-title":["Cancer Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877782118305344?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877782118305344?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T15:57:21Z","timestamp":1573055841000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1877782118305344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":32,"alternative-id":["S1877782118305344"],"URL":"https:\/\/doi.org\/10.1016\/j.canep.2018.12.002","relation":{},"ISSN":["1877-7821"],"issn-type":[{"value":"1877-7821","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Increase in survival for patients with mantle cell lymphoma in the era of novel agents in 1995\u20132013: Findings from Texas and national SEER areas","name":"articletitle","label":"Article Title"},{"value":"Cancer Epidemiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canep.2018.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}